Table 1 Baseline characteristics in the clinical study
Placebo (n = 45) | NFMD ALL (n = 46) | Placebo TID (n = 27) | NFMD 40 mg TID (n = 20) | |
|---|---|---|---|---|
Age (yrs) | 72.1 (6.9) | 73.5 (6.9) | 70.4 (5.7) | 72.2 (6.6) |
Age range | 62–87 | 59–85 | 62–83 | 59–84 |
Male | 87% | 85% | 96% | 95% |
CDR Sum of Boxes | 5.1 (3.2) | 4.9 (1.8) | 4.4 (2.3) | 4.7 (1.8) |
MMSE | 23.0 (3.3) | 23.1 (3.9) | 23.6 (3.3) | 23.4 (3.3) |
ISLT | 14.3 (5.4) | 13.6 (5.9) | 14.2 (6.2) | 14.1 (4.9) |
Timed Up and Go (seconds) | 13.5 (6.4) | 12.7 (3.7) | 13.3 (5.2) | 13.3 (3.8) |
Fluctuating cognition | 60% | 61% | 55% | 60% |
Visual hallucinations | 55% | 61% | 48% | 70% |
REM sleep disorder | 73% | 59% | 78% | 70% |
Parkinsonism | 84% | 78% | 78% | 75% |
≥2 core clinical features* | 87% | 83% | 82% | 90% |
Carbidopa-Levodopa | 29% | 28% | 37% | 40% |
Anti-depressants | 49% | 54% | 52% | 65% |
Clonazepam | 15% | 15% | 26% | 30% |
Baseline plasma ptau181<2.2 pg/mL | 51% | 55% | 54% | 55% |
